Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay
TipRanks (Mon, 23-Mar 1:39 PM ET)
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition
Business Wire (Mon, 23-Mar 11:00 AM ET)
Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning
Benzinga (Mon, 23-Mar 10:26 AM ET)
Aurinia Reshapes Executive Team as Board Chair Kevin Tang Becomes CEO
TipRanks (Mon, 23-Mar 9:32 AM ET)
Aurinia Pharmaceuticals appoints Kevin Tang as CEO
Seeking Alpha News (Mon, 23-Mar 8:22 AM ET)
Aurinia Announces Management Transition
Business Wire (Mon, 23-Mar 8:00 AM ET)
Market Chameleon (Thu, 26-Feb 3:38 AM ET)
Business Wire (Thu, 26-Feb 6:00 AM ET)
Business Wire (Thu, 19-Feb 6:00 AM ET)
Aurinia Sets November 4 for Earnings Reveal—Investors Eye Business Update as New Therapies Advance
Market Chameleon (Tue, 4-Nov 5:41 AM ET)
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.
As of March 27, 2026, AUPH stock price declined to $14.27 with 1,014,813 million shares trading.
AUPH has a beta of 0.22, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.01 to the broad based SPY ETF.
AUPH has a market cap of $1.88 billion. This is considered a Small Cap stock.
Last quarter Aurinia Pharmaceuticals - Common Shares reported $77 million in Revenue and $.26 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.05.
In the last 3 years, AUPH traded as high as $16.54 and as low as $4.71.
The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, JSMD.
AUPH has outperformed the market in the last year with a price return of +67.5% while the SPY ETF gained +12.8%. However, in the short term, AUPH had mixed performance relative to the market. It has underperformed in the last 3 months, returning -12.2% vs -7.9% return in SPY. But in the last 2 weeks, AUPH shares have fared better than the market returning -0.7% compared to SPY -4.5%.
AUPH support price is $14.22 and resistance is $14.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.